05:22 AM EDT, 10/25/2024 (MT Newswires) -- Revolution Medicines ( RVMD ) said Friday that data from a phase 1/1b study of its drug candidate RMC-9805 showed "encouraging" initial safety, tolerability and antitumor activity in patients with previously treated pancreatic ductal adenocarcinoma.

The 179-patient study demonstrated "an encouraging safety profile and was generally well-tolerated across dose levels," the company said.

Pancreatic cancer patients who received a first dose of RMC-9805 at least 14 weeks prior to the data cutoff date achieved a 30% objective response rate, with a disease control rate of 80%.

Shares of Revolution Medicines ( RVMD ) were up more than 2% in Friday's premarket activity.

Price: 48.50, Change: +1.25, Percent Change: +2.65